NCT01247571 · STUDY IN CONTEXT

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Complete and Partial Tumor Response by RECIST 1.0. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Eligible and Treated Patients

→

primary · POSTED

Progression-free survival is the period from study entry until disease progression, death or date of last contact. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Eligible and treated patients

→

primary · POSTED

Grade 3 or higher adverse events were graded by CTCAE v4.

Eligible and Treated Patients

→

secondary · POSTED

Progression-free survival is the period from study entry until disease progression, death or date of last contact

Eligible and Treated Patients

→

secondary · POSTED

The observed length of life from entry into the study to death or the date of last contact.

Eligible and treated patients

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-uterine-carcinosarcoma
nct id: NCT01247571
trial label: Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 5
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0000
source section id
NCT01247571-om-0000
source outcome index
0
endpoint
Objective Tumor Response (Complete or Partial)
endpoint definition
Complete and Partial Tumor Response by RECIST 1.0. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
time origin
CT scan or MRI if used to follow lesion(s) for measurable disease every other cycle for the first 6 mnths; then every 3 mnths thereafter until dx progression is confirmed; also repeat any other time clinically indicated, assessed up to 6 months.
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Eligible and Treated Patients
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0001
source section id
NCT01247571-om-0001
source outcome index
1
endpoint
Percentage of Participants With Progression-free Survival (PFS) at 6 Months
endpoint definition
Progression-free survival is the period from study entry until disease progression, death or date of last contact. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
time origin
6 months
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Eligible and treated patients
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0002
source section id
NCT01247571-om-0002
source outcome index
2
endpoint
Number of Patients With Grade 3 or Higher Adverse Events
endpoint definition
Grade 3 or higher adverse events were graded by CTCAE v4.
time origin
Every cycle while on treatment
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Eligible and Treated Patients
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0003
source section id
NCT01247571-om-0003
source outcome index
3
endpoint
Progression-free Survival
endpoint definition
Progression-free survival is the period from study entry until disease progression, death or date of last contact
time origin
From start of treatment to time of progression or death, assessed up to 5 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eligible and Treated Patients
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0004
source section id
NCT01247571-om-0004
source outcome index
4
endpoint
Overall Survival
endpoint definition
The observed length of life from entry into the study to death or the date of last contact.
time origin
Time from start of treatment to time of death or the date of last contact, assessed up to 5 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eligible and treated patients
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0000
arm key
OG000
arm label
Pazopanib
regimen
Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01247571-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0001
arm key
OG000
arm label
Pazopanib
regimen
Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01247571-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0002
arm key
OG000
arm label
Pazopanib
regimen
Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01247571-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0003
arm key
OG000
arm label
Pazopanib
regimen
Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01247571-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
outcome key
om-0004
arm key
OG000
arm label
Pazopanib
regimen
Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01247571-om-0004#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT01247571
harm key
EG000
source section id
NCT01247571-ae
event group key
EG000
event group label
Pazopanib
serious affected
6
serious at risk
19
other affected
19
other at risk
19
frequency threshold
0
collection period
All Adverse Events (AEs) occurring during treatment and up to 30 days after stopping the study treatment are reported. Also reported are Serious Adverse Events (SAEs) for up to 5 years after stopping study treatment.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice